STOCK TITAN

Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.

Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.

Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.

For more information, please visit www.karyopharm.com.

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced a webcast on December 12, 2022, to present updated Phase 1 study results on selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. Key opinion leaders, including Dr. Haris Ali and Dr. Srdan Verstovsek, will discuss data and the treatment landscape. The webcast will be accessible on the company's investor website. Karyopharm also has multiple presentations scheduled at the ASH 2022 Annual Meeting, focusing on its cancer therapies, particularly XPOVIO, which has various regulatory approvals worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has entered into a securities purchase agreement for a private placement expected to yield $165 million. The company will sell 31,791,908 shares of common stock at $5.19 per share, along with warrants for an additional 9,537,563 shares at an exercise price of $6.36. Proceeds will fund clinical development of selinexor and eltanexor, and general corporate purposes. The placement is set to close around December 7, 2022, pending standard conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 6,100 shares and 4,200 restricted stock units (RSUs) to two new employees as of November 30, 2022. The stock options have an exercise price of $5.29 per share, equivalent to Karyopharm's closing stock price on the grant date. Both stock options and RSUs will vest over four years, with specific conditions for early exercise tied to employment termination scenarios. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at facilitating recruitment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
none
Rhea-AI Summary

Karyopharm Therapeutics (NASDAQ: KPTI), a leader in novel cancer therapies, announced its participation in two upcoming investor conferences in November 2022. The Jefferies 2022 London Healthcare Conference is scheduled for November 15, 2022, at 3:35 a.m. ET, featuring a fireside chat. The Piper Sandler 34th Annual Healthcare Conference will take place on November 29, 2022, at 11:30 a.m. ET, with a podium presentation. Webcasts of both events will be accessible for 90 days post-event on the company's investor webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
Rhea-AI Summary

Karyopharm Therapeutics (KPTI) reported Q3 2022 total revenue of $36.1 million, with net product revenue from XPOVIO at $32.0 million, a 20% increase from Q3 2021. The company initiated a Phase 3 study for selinexor as maintenance therapy in advanced endometrial cancer. Encouraging data from a Phase 1 study of selinexor combined with ruxolitinib in myelofibrosis was highlighted, showing positive efficacy results. Karyopharm maintains its 2022 revenue guidance of $155 million to $165 million, emphasizing a cash runway into early 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced promising results from a Phase 1 study on selinexor combined with ruxolitinib for treatment-naïve myelofibrosis. Preliminary efficacy showed 79% of patients achieved a ≥35% reduction in spleen volume at 12 weeks, with 86% at 24 weeks. The treatment also demonstrated significant symptom reduction in 69% of evaluable patients. Common adverse events were manageable, with no dose-limiting toxicities reported. Data on selinexor's effectiveness in triple-class refractory multiple myeloma will also be presented at the upcoming ASH Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 23,200 shares and 16,000 restricted stock units (RSUs) to seven new employees as of October 31, 2022. These awards were made under the 2022 Inducement Stock Incentive Plan as an incentive for new hires in line with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $4.76 per share and will vest over four years, while RSUs will also vest over the same period. Both awards include conditions related to employment status and change in control provisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) and Menarini Group announced that the European Commission has granted orphan medicinal product designation for selinexor to treat myelofibrosis (MF). This follows the FDA's orphan designation for selinexor in May 2022. Karyopharm is studying selinexor as a monotherapy and in combination with ruxolitinib for MF. Selinexor is a first-in-class XP01 inhibitor. The designation provides financial and regulatory incentives, including 10-year marketing exclusivity in the EU after approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2022 financial results on November 3, 2022. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead product, XPOVIO® (selinexor), which is approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets. Investors interested in KPTI should tune in to the call for key financial insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
conferences earnings
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced on October 3, 2022, the granting of stock options and restricted stock units (RSUs) to new employees, including Executive VP Lisa DiPaolo. On September 30, 2022, a stock option to purchase 1,200 shares at $5.46 per share was awarded to a new hire, while DiPaolo received options for 100,000 shares and 65,000 RSUs at the same exercise price. The awards vest over four years, linked to ongoing employment. These inducements comply with Nasdaq rules and aim to attract talent essential for the company's innovative cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none

FAQ

What is the current stock price of Karyopharm Therapeutics (KPTI)?

The current stock price of Karyopharm Therapeutics (KPTI) is $0.635 as of December 20, 2024.

What is the market cap of Karyopharm Therapeutics (KPTI)?

The market cap of Karyopharm Therapeutics (KPTI) is approximately 82.5M.

What is Karyopharm Therapeutics' main focus?

Karyopharm Therapeutics specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other major diseases.

What is XPOVIO® (selinexor)?

XPOVIO® is a first-in-class, oral exportin 1 (XPO1) inhibitor approved for the treatment of multiple oncology indications, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL).

What recent achievements has Karyopharm reported?

Karyopharm recently announced promising long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib for myelofibrosis. The company also reported strong financial performance with total revenue of $146.0 million for the year 2023.

Who are Karyopharm's global partners?

Karyopharm has partnered with Antengene, Menarini, Neopharm, and FORUS to market XPOVIO in international markets, including Europe, China, South Korea, and Israel.

What are Karyopharm's financial highlights?

For Q4 2023, Karyopharm reported total revenue of $33.7 million and a full-year revenue of $146.0 million. The company had a cash position of $192.4 million as of December 31, 2023.

What are the key indications for XPOVIO?

XPOVIO is approved for use in combination with Velcade and dexamethasone for multiple myeloma, in combination with dexamethasone for heavily pre-treated multiple myeloma, and as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

What is the significance of Karyopharm's research on nuclear export proteins?

Karyopharm's research targets nuclear export dysregulation, a fundamental mechanism of oncogenesis, aiming to develop therapies that inhibit this process and treat various cancers effectively.

How does Karyopharm support clinical trials and research?

Karyopharm is engaged in several mid- and late-stage clinical trials across multiple high unmet need cancer indications, including endometrial cancer and myelofibrosis. The company also collaborates with global partners and research institutions to advance its pipeline.

What are the safety considerations for XPOVIO?

Common treatment-emergent adverse events for XPOVIO include nausea, vomiting, diarrhea, and neutropenia. Patients are advised not to breastfeed during treatment. Full prescribing information is available on www.XPOVIO.com.

How can I get more information about Karyopharm's products or clinical trials?

For more information, you can contact Karyopharm's Medical Information department at +1 (888) 209-9326 or via email at medicalinformation@karyopharm.com.

Karyopharm Therapeutics Inc.

Nasdaq:KPTI

KPTI Rankings

KPTI Stock Data

82.52M
117.36M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON